Rchr
J-GLOBAL ID：200901043078879261
Update date: Sep. 20, 2024
Hazama Shoichi
ハザマ ショウイチ | Hazama Shoichi
Affiliation and department：
Job title：
Associate Professor
Research field (5)：
Digestive surgery
, Pharmacology
, Immunology
, Molecular biology
, Genetics
Research keywords (1)：
colorectal surgery, cancer immunology immunotherapy, molecular biology
Research theme for competitive and other funds (29)：
- 2022 - 2024 A mini-organ culture system with cancer immune microenvironment recapitulating in vivo
- 2021 - 2024 大腸癌に対するFOLFOXIRI療法における副作用診断チップの開発
- 2021 - 2024 Can Anti-EGFR Antibodies Turn Colorectal Cancer into Hot Tumors?
- 2021 - 2024 がん発症・進展過程におけるYAPの活性化の機械的制御機構の解明
- 2021 - 2024 大腸癌肝転移に関与する癌細胞由来マイクロRNAの同定と制御するメカニズムの解明
- 2021 - 2024 Identification of tumor-specific antigens to construct the novel combination immunotherapy
- 2020 - 2023 Development of new immunotherapy for metastatic pancreatic cancer by applying organoids derived from circulating tumor cells in blood.
- 2020 - 2023 CyTOFによる大腸腫瘍浸潤CD4+FOXP3+細胞の解析と予後因子としての役割
- 2019 - 2022 MSI related predictive biomarkers of response to immune checkpoint inhibitors for patients with metastatic urological cancers
- 2019 - 2021 Creation of lyph node organoids enabling mechanical control of immunity
- 2018 - 2021 Identification for biomarkers in cancer peptide vaccine therapy with immune checkpoint inhibitors
- 2018 - 2021 Novel immunotherapy for pancreatic cancer by the multi-HLA binding peptides derived from cancer stemness molecules.
- 2017 - 2020 Analysis of microRNA in cancer microenvironment involved in colorectal liver metastasis
- 2017 - 2019 Analysis of microRNA in the cancer cell and stromal tissue to explore predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer.
- 2009 - 2011 Novel strategy for prediction of toxicity and efficacy of chemotherapy for patients with metastatic colorectal cancer.
- 2007 - 2008 The polymorphisms can predict the adverse effects of chemotherapy in patients with colorectal cancer
- 2004 - 2005 Combination therapy with immunotherapy and chemotherapy for pancreatic cancer. -Aim at the standardization of clinical trial for immuno-chemotherapy-
- 2003 - 2005 Immunotherapy for prevention of postoperative recurrence in pancreatic cancer using cell therapy and vaccine therapy
- 2003 - 2003 膵癌に対するMUC1刺激樹状細胞療法の臨床研究-樹状細胞マイクロアレイ解析を含めて-
- 2000 - 2002 Relation between nm23-H1 expression and effect of chemotherapy for hepatocellular carcinoma
- 2000 - 2002 Immunotherapy using cytotoxic T cell and peptide vaccine for pancreatic cancer
- 1999 - 2001 Targeting chemotherapy with NM 23-H1 for carcinoma of the esophagus
- 1998 - 1998 食道癌のNM23-H1の発現に基づいた化学療法の開発
- 1997 - 1998 Immunogene therapy for the gostrointestinal malignancies using tumor cells engineered to secrete cytokines and chemokines
- 1996 - 1998 Adoptive immunotherapy using MUC1 specific cytotoxic T lymphocytes for pancreatic cancer
- 1996 - 1997 新しい癌ワクチン療法におけるinterleuk in-15遺伝子導入療法の有用性
- 1995 - 1995 IL-1R antaqonist発現による胃癌悪性度評価と遺伝子療法への応用
- 1993 - 1995 New Immunotherapy for hepatocellular carcinoma after hepatectomy
- 1990 - 1992 New immunotherapy for prevention of liver metastasis from colorectal cancer after surgery.
Show all
Papers (828)：
-
Kei Furuya, Masao Nakajima, Ryouichi Tsunedomi, Yuki Nakagami, Ming Xu, Hiroto Matsui, Yukio Tokumitsu, Yoshitaro Shindo, Yusaku Watanabe, Shinobu Tomochika, et al. High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer. BMC cancer. 2024. 24. 1. 165-165
-
中島 正夫, 徳光 幸生, 新藤 芳太郎, 松井 洋人, 坂元 亨宇, 硲 彰一, 井岡 達也, 永野 浩昭. 新規複合免疫療法による肝細胞癌の腫瘍免疫原性向上の試み. 肝臓. 2023. 64. Suppl.3. A895-A895
-
Tsunenori Yamamoto, Ryouichi Tsunedomi, Masao Nakajima, Nobuaki Suzuki, Shin Yoshida, Shinobu Tomochika, Ming Xu, Yuki Nakagami, Hiroto Matsui, Yukio Tokumitsu, et al. IL-6 Levels Correlate with Prognosis and Immunosuppressive Stromal Cells in Patients with Colorectal Cancer. Annals of Surgical Oncology. 2023
-
Masao Nakajima, Shoichi Hazama, Yukio Tokumitsu, Yoshitaro Shindo, Hiroto Matsui, Satoshi Matsukuma, Yuki Nakagami, Koji Tamada, Keiko Udaka, Michiie Sakamoto, et al. A phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial. Hepatology research : the official journal of the Japan Society of Hepatology. 2023. 53. 7. 649-660
-
Yuta Kimura, Ryouichi Tsunedomi, Kiyoshi Yoshimura, Satoshi Matsukuma, Yoshitaro Shindo, Hiroto Matsui, Yukio Tokumitsu, Shin Yoshida, Michihisa Iida, Nobuaki Suzuki, et al. ASO Visual Abstract: Immune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells. Annals of surgical oncology. 2023. 30. 3. 1660-1661
ｍore...
MISC (670)：
-
兼定航, 恒富亮一, 硲彰一, 荻原宏是, 浜本義彦, 新藤芳太郎, 松井洋人, 徳光幸生, 吉田晋, 飯田通久, et al. イリノテカン毒性と関連するR3HCC1遺伝子における一塩基多型. 山口医学. 2023. 72. 3
-
永坂岳司, 入谷光洋, 大場光芳, 中村憲章, 谷岡洋亮, 岡脇誠, 山口佳之, 硲彰一, 永野浩昭. MLH1MethylationおよびBRAF V600E変異同定DNA chipによるリンチ症候群除外診断技術の確立と実用化にむけて. 日本大腸肛門病学会雑誌(Web). 2021. 74. 9
-
Megumi Yamanaka, Mohamed Elbadawy, Hayasi Kimika, Goto Yuta, Tsunedomi Ryouichi, Hazama Shoichi, Nagano Hiroaki, Yoshida Toshinori, Shibutani Makoto, Ichikawa Ryo, et al. Establishment of the method of three-dimensional organoid culture derived from liver tissues of non-alcoholic steatohepatitis (NASH) model mice. Proceedings for Annual Meeting of The Japanese Pharmacological Society. 2020. 93. 1-SS-22
-
YAMANAKA Megumi, MOHAMED Elbadawy, HAYASHI Kimika, GOTO Yuta, TSUNEDOMI Ryouichi, HAZAMA Shoichi, NAGANO Hiroaki, YOSHIDA Toshinori, SHIBUTANI Makoto, ICHIKAWA Ryo, et al. Exploring for new biomarkers using liver organoids derived from nonalcoholic steatohepatitis (NASH) model mice. Annual Meeting of the Japanese Society of Toxicology. 2020. 47.1. P-36E
-
中上裕有樹, 中上裕有樹, 硲彰一, 硲彰一, 玉田耕治, 土肥俊, 坂元亨宇, 加藤直也, 齋藤彰, 安達圭志, et al. 切除可能なHCCに対する新規術前後ペプチドワクチン療法症例の組織病理・免疫的反応. 日本癌治療学会学術集会(Web). 2020. 58th
ｍore...
Patents (15)：
Books (5)：
-
消化器外科学レビュー2005-最新主要文献と解説
総合医学社 2005
-
消化器外科学レビュー2004-最新主要文献と解説-
総合医学社 2004
-
別冊・医学のあゆみ 免疫疾患、Ver.2
医歯薬出版 2002
-
経験すべき下部消化管手術
メジカルビュー社 2001
-
サイトカイン・ケモカイン遺伝子導入癌細胞を用いた消化器癌遺伝子療法の開発
[硲彰一(山口大学理学部)] 1999
Lectures and oral presentations (169)：
-
消化器がんに対する免疫療法の最前線
(第34回日本バイオセラピー学会学術集会 2021)
-
新しいがん免疫療法ーCold tumorをHot tumorにー
(第30回日本癌病態治療研究会 2021)
-
最近の免疫研究をふり返って〜免疫研究の今後〜
(第30回日本癌病態治療研究会 2021)
-
消化器がんの高免疫原性ネオアンチゲン同定におけるAIの有用性
(第18回日本免疫治療学会学術集会 2021)
-
消化器癌に対する新規複合免疫療法
(第120回日本外科学会定期学術集会 2021)
ｍore...
Education (2)：
- - 1990 山口大学大学院 医学研究科 医学研究科 外科系専攻
- - 1986 Yamaguchi University Faculty of Medicine
Professional career (1)：
Work history (4)：
- 2016/04 - 現在 Yamaguchi University School of Medicine
- 2007/04/01 - 2016/10/23 YAMAGUCHI UNIVERSITY Graduate School of Medicine(Medicine) Associate Professor
- 2002/04/01 - 2007/03/31 YAMAGUCHI UNIVERSITY Lecturer
- 1993/08/16 - 2002/03/31 YAMAGUCHI UNIVERSITY Research Associate
Association Membership(s) (10)：
ESMO (European Society for Medical Oncology)
, 日本消化器外科学会
, 日本外科系連合学会
, ASCO (American Society of Clinical Oncology)
, 日本バイオセラピィ学会
, 日本臨床外科学会
, 日本大腸肛門病学会
, 日本癌治療学会
, 日本癌学会
, 日本外科学会
